MJA 216 5 21 March cover

Issues

Volume 216 Issue 5

21 March 2022

News

21 March 2022 Free

News briefs

Adolescent drug use does not affect future life success when stopped early Young people who use drugs but quit by early adulthood are, on average, not harming their future life chances, according to Australian research which tracked thousands of people over a 16‐year period. Published in Addiction Research and Theory, the study examined the extent to which cannabis and amphetamine use up to 21 years of age predicts life success at 30 years of age. The study took into account a wide range of prior life experiences and behaviour. The authors used data on 2350 children born to mothers in the Mater–University of Queensland Study of Pregnancy which began 40 years ago and has followed up participants at key life stages. The participants were tested at 14 years of age for IQ, mental health, and aggression/delinquency. Information from mothers was also analysed, including number of partners and the child’s contact with police. Cannabis and amphetamine use was self‐reported at specific age points (21 and 30 years). The authors also interviewed participants at age 21 years about behaviours linked to past drug‐taking (eg, drug‐related disorder). Life success was measured at age 30 years and defined according to three categories: socio‐economic, quality of life, and quality of intimate relationships. The results showed that more than one in five (22%) had ever had a cannabis use disorder and 4% had had problematic amphetamines use. Age of onset ranged from 15 to 19 years and the participants reported high levels of drug use. The proportion of participants at age 21 years who reported problematic drug use was 19% for cannabis, 0.7% for amphetamines, and 3% for those using both drugs. Of these, the issues persisted at 30 years of age for more than one‐third (36%) using cannabis, and 60% of those using cannabis and amphetamines. A majority of those who had ever met the criteria for problematic drug use were no longer using at clinically significant levels by age 21 years, according to the findings. However, the use of cannabis at age 30 years was strongly related to achievement. This was also dose related; high use in adulthood was associated with the highest rates of poor life success. https://www.tandfonline.com/doi/full/10.1080/16066359.2022.2032679 Serious allergic reactions to food among children stabilise since guideline changes The rate of increase in serious allergic reactions to food among children has flattened since changes to Australian infant feeding guidelines, a study from the Murdoch Children’s Research Institute, published in the Journal of Allergy and Clinical Immunology, has found. The Australasian Society of Clinical Immunology and Allergy (ASCIA) infant feeding and food allergy prevention guidelines changed in response to published studies over the past 15 years, from a recommendation to “delay” allergenic foods (1999 to 2007) to “not delay” (2008) and then later to “introduce early and often” (since 2016). The study examined national emergency department data for food anaphylaxis during three different time periods: 1998–1999 to 2006–2007; 2007–2008 to 2014–2015; and 2015–2016 to 2018–2019. A total of 37 132 anaphylaxis admissions were recorded over the timespan. “In children, aged 1 to 4 years, the yearly rate of increase dropped from 17.6% a year between 1999 and 2007, to 6.2% a year between 2008 and 2015 and then 3.9% a year since 2016,” the authors wrote. “A slowing in the rates of increase in food anaphylaxis admissions also occurred in those aged 5–14 years, born after the 2008 changes. These changes were not seen in older teens aged 15 and over who were born before 2008, who could not have benefited from the changing guidelines. While we did see a spike in children aged less than one year, this is most likely due to earlier hospital presentations of pre‐existing food allergy following introduction of allergenic solids in the first year of life.” The researchers cautioned that it was important not to be complacent, as overall food anaphylaxis hospital admission rates had still increased and there was an unmet need for effective treatments that could induce remission. https://www.jacionline.org/article/S0091-6749(22)00081-1/pdf

Perspectives

Medical education

Ethics and law

Reflection

Editorials

Research

Guideline summary

Letters

Mental health 21 March 2022 Free

Social and occupational outcomes for young people who attend early intervention mental health services

To the Editor: We must clarify that the findings of Iorfino and colleagues1 do not apply to headspace clients. This understandable misperception comes from the article’s title, “early intervention mental health services”, and participants coming from “clinics” that “provide both primary care services (headspace) and more specialised services”. Quotes from an InSight+ article2 and the accompanying editorial3 infer that the findings generalise to headspace, but they do not. Although some participants in the Iorfino study came from two headspace‐branded centres, they also included young people accessing specialised services. This is evident in the limitations: “our sample was restricted to young people who remained in contact with the service for at least two years … biasing our sample towards people who required ongoing care and were accordingly more likely to have poorer outcomes”. Generally, headspace does not provide care over a period of two years or more; centres typically provide brief episodes of care, befitting young people with mild to moderate presentations for common mental health problems. The average number of sessions is 4.4 (standard deviation [SD], 6.2); 98% of clients receive 20 sessions or fewer. A negligible 0.4% of clients are still receiving care at two years. Average time between the first and last session is 73.7 days (SD, 120), about 2.5 months (headspace 2015–2021, national unpublished data). Clarification that the findings are not representative of, nor generalisable to, headspace clients is essential; the headspace initiative is not targeted at young people who need more sustained mental health care. The results are inconsistent with reported outcomes for 24 034 headspace clients from 55 fully established centres.4 Significant improvement in the Social and Occupational Functioning Assessment Scale (SOFAS) scores was evident for 37.1% of headspace clients, 43.4% had no significant change, and 19.5% significantly deteriorated. Updated outcomes are forthcoming. Importantly, multiple outcomes must be considered for headspace clients; these are young people with diverse early intervention needs — the single‐item, clinician‐rated SOFAS is insufficient to ascertain meaningful outcomes. Despite the inability to generalise from Iorfino’s study to the national headspace centre network, we agree that young people with complex and persisting mental health conditions require more resource‐intensive responses than headspace primary care services were designed for.

Debra J Rickwood · Jason Trethowan · Annette Carruthers

Mental health 21 March 2022 Free

Social and occupational outcomes for young people who attend early intervention mental health services

To the Editor: Iorfino and colleagues1 reported that “two in three young people with emerging mental disorders did not experience meaningful improvement in social and occupational functioning during two years of early intervention care”. Their sample was drawn from two headspace sites. This sounds alarming, especially considering that the study is exemplary in its longitudinal design, large sample size, and robust statistical analyses. Nevertheless, clinicians should be mindful of making too much of these results. The primary weakness of this study is the measure used: the Social and Occupational Functioning Assessment Scale (SOFAS). A systematic review of measures of functioning considered evaluating the SOFAS, yet excluded it based on the grounds that “the SOFAS has been superseded by the Personal and Social Performance Scale (PSP), which demonstrates stronger psychometric performance”.2 A study in 2007 stated that “the PSP scale is proposed as an improvement over the [Global Assessment of Functioning] and SOFAS because of its clear operational instructions on how to rate the severity of disability and its distinction between levels of impairment”.3 A similar issue was noted in 2000.4 Suffice to say, the SOFAS is a superseded measure of social and occupational functioning. This is apparent at the theoretical level. The SOFAS is a single item measure, rated on a scale of 0–100, for both social and occupational functioning. How is a clinician meant to score this measure when a young person presents functioning highly in their schooling, yet poorly in their social life? Or when things are going well with friends, yet poorly with their family? With this in mind, it is no surprise that three out of the four trajectories for young people’s mental health journeys identified by Iorfino and colleagues1 demonstrated no significant improvement. This is indicative of a broader issue identified in a systematic review of 189 articles, which reported that only nine mental health outcome measures in the published literature examined functional outcomes. Of these, “no measures were designed specifically for young people aged 12 to 25 years”.5 In short, the SOFAS is an out‐of‐date, adult measure with poor inter‐rater reliability. The study by Iorfino et al1 is what we need, but not what we are ready for. There is an urgent need in youth mental health services to have valid, reliable measures of social and occupational functioning that have good construct validity. There is an urgent research need for the development of such measures that have robust psychometric properties and clinical utility. Until this issue is resolved, attempting to predict pathways of care, or measure the efficacy of these services at a population level, will remain a guessing game. Future studies should focus on the development and evaluation of these measures. The collateral damage if researchers continue to use these measures will be the young people in need of early intervention.

Peter J Lenehan

Next Issue Volume 216 Issue 6

View more
MJA 216 6 4 April cover
News 4 April 2022 Free

News briefs

Perspectives 4 April 2022 Free

Concussion in Aboriginal and Torres Strait Islander peoples: what is the true epidemiology?

Jonathan Bullen · Trish Hill‐Wall · Elizabeth Thomas · Richard Norman · Gill Cowen

Perspectives 4 April 2022 Free

Realising the potential: leveraging clinical quality registries for real world clinical research

Susannah Ahern · Belinda J Gabbe · Sally Green · Carol L Hodgson · Erica M Wood · John R Zalcberg OAM · Tsharni Zazryn

Perspectives 4 April 2022 Open Access

Population DNA screening for medically actionable disease risk in adults

For the DNA Screen Investigator Group†

Previous Issue Volume 216 Issue 4

View more
MJA216 4 7 Mar cover
News 7 March 2022 Free

News briefs

Perspectives 7 March 2022 Free

Congenital cytomegalovirus: the case for targeted infant screening in Australia

Allison Reid · Asha C Bowen · Christopher G Brennan‐Jones · Jafri B Kuthubutheen

Perspectives 21 February 2022 Free

Does the FDA‐approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?

Andrew Gleason · Scott Ayton · Ashley I Bush

Perspectives 14 February 2022 Free

The art and science of clinicians leading change

Sabe Sabesan · Lynden Roberts

Subscribe to MJA email alerts

No spam, you can unsubscribe anytime you want.

By providing your information, you agree to our Terms of Use and our Privacy Policy.

Thanks for Subscribing! Tell us more

Your email updates will use your name.

Good one! Your updates are coming

Thank you for subscribing to the MJA email alerts. Receive the latest content in your inbox.